In This Issue

1 In This Issue of Diabetes Care

Editor’s Commentary

3 Diabetes Care in 2020: Following and Leading the Stories of Diabetes
M.C. Riddle

Perspectives in Care

5 Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes

Commentaries

13 Insulin Dosing for Fat and Protein: Is it Time?
C.E.M. Smart, B.R. King, and P.E. Lopez

16 Genetics of Type 1 Diabetes Comes of Age
M.J. Redondo and P. Concannon

Continuous Glucose Monitoring For Type 1 Diabetes

19 Putting Continuous Glucose Monitoring to Work for People With Type 1 Diabetes
K.K. Hood, L.A. DiMeglio, and M.C. Riddle

22 Distinct Patterns of Daily Glucose Variability by Pubertal Status in Youth With Type 1 Diabetes
J. Zhu, L.K. Volkeling, and L.M. Laffel

29 Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial

37 Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMSAIR Study

44 Predictors of Recurrent Severe Hypoglycemia in Adults With Type 1 Diabetes and Impaired Awareness of Hypoglycemia During the HypoCOMPaSS Study

53 Continuous Glucose Monitoring in People With Type 1 Diabetes on Multiple-Dose Injection Therapy: The Relationship Between Glycemic Control and Hypoglycemia

Clinical Care/Education/Nutrition/Psychosocial Research

59 Amount and Type of Dietary Fat, Postprandial Glycemia, and Insulin Requirements in Type 1 Diabetes: A Randomized Within-Subject Trial

67 Urinary and Serum Angiogenic Markers in Women With Preexisting Diabetes During Pregnancy and Their Role in Preeclampsia Prediction

74 Excessive Weight Gain Before and During Gestational Diabetes Mellitus Management: What is the Impact?
R.A. Barnes, T. Wong, G.P. Ross, M.M. Griffiths, C.E. Smart, C.E. Collins, L. MacDonald-Wicks, and J.R. Flack

82 Absence of Islet Autoantibodies and Modestly Raised Glucose Values at Diabetes Diagnosis Should Lead to Testing for MODY: Lessons From a 5-Year Pediatric Swedish National Cohort Study

Epidemiology/Health Services Research

90 Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis

98 Maternal Gestational Diabetes Mellitus and Newborn DNA Methylation: Findings From the Pregnancy and Childhood Epigenetics Consortium

J.L. Harding, S.R. Benoit, E.W. Gregg, M.E. Pavkov, and L. Perreault
Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in Colorado Children, 2010–2017

Risk of Rapid Kidney Function Decline, All-Cause Mortality, and Major Cardiovascular Events in Nonalbuminuric Chronic Kidney Disease in Type 2 Diabetes
O. Buyadza, D.J. Magliano, A. Salm, D.N. Koye, and J.E. Shaw

Oxidatively Damaged DNA/RNA and 8-Isoprostane Levels Are Associated With the Development of Type 2 Diabetes at Older Age: Results From a Large Cohort Study
B. Schöttler, Y. Xuan, X. Gao, A. Anursutri, and H. Brenner

Vertebral Fractures in Individuals With Type 2 Diabetes: More Than Skeletal Complications Alone

Childhood Pancreatitis and Risk for Incident Diabetes in Adulthood

Early Outcomes From the English National Health Service Diabetes Prevention Programme

Emerging Therapies: Drugs and Regimens

Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1052 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study

Pathophysiology/Complications

Genetic Variants Predisposing Most Strongly to Type 1 Diabetes Diagnosed Under Age 7 Years Lie Near Candidate Genes That Function in the Immune System and in Pancreatic β-Cells
J.R.J. Inshaw, A.J. Cutler, D.J.M. Crouch, L.S. Wicker, and J.A. Todd

High Concentration of Medium-Sized HDL Particles and Enrichment in HDL Paraoxonase 1 Associate With Protection From Vascular Complications in People With Long-standing Type 1 Diabetes

Effect of Surgical Versus Medical Therapy on Diabetic Kidney Disease Over 5 Years in Severely Obese Adolescents With Type 2 Diabetes

Cardiovascular and Metabolic Risk

Appropriate Shocks and Mortality in Patients With Versus Without Diabetes With Prophylactic Implantable Cardioverter Defibrillators

White Matter Connectivity Abnormalities in Prediabetes and Type 2 Diabetes: The Maastricht Study

Muscle Oxygen Supply and Use in Type 1 Diabetes, From Ambient Air to the Mitochondrial Respiratory Chain: Is There a Limiting Step?

Prognostic Importance of Resistant Hypertension in Patients With Type 2 Diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study

Insulin Sensitivity and Renal Hemodynamic Function in Metformin-Treated Adults With Type 2 Diabetes and Preserved Renal Function

Sleep and HbA1c in Patients With Type 2 Diabetes: Which Sleep Characteristics Matter Most?

Cancer Use Is Associated With Increased Risk for Diabetic Ketoacidosis in Adults With Type 1 Diabetes: Findings From the TID Exchange Clinic Registry
G.L. Kinney, H.K. Akturk, D.L. Foster, and V.N. Shah

Consensus Report

Diabetes Digital App Technology: Benefits, Challenges, and Recommendations. A Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group

Issues and Events

Issues and Events

e-Letters – Observations

Dietary Patterns of Insulin Pump and Multiple Daily Injection Users During Type 1 Diabetes Pregnancy
S.L. Neoh, J.M. Yamamoto, D.S. Feig, and H.R. Murphy, on behalf of the CONCEPT Collaborative Group
e-Letters – Comments and Responses

e8 Comment on Norhammar et al. Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study. Diabetes Care 2019;42:1504–1511
H. Li, S. Tian, and L.-q. Kong

e9 Response to Comment on Norhammar et al. Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study. Diabetes Care 2019;42:1504–1511
A. Norhammar, B. Kjellström, N. Habib, A. Gustafsson, B. Klinge, Å. Nygren, P. Näsman, E. Svenungsson, and L. Rydén

e10 Comment on Trinh et al. Successful Treatment of Immune Checkpoint Inhibitor–Induced Diabetes With Infliximab. Diabetes Care 2019;42:e153–e154
A. Galligan, B. Krishnamurthy, and T.W. Kay

e11 Response to Comment on Trinh et al. Successful Treatment of Immune Checkpoint Inhibitor–Induced Diabetes With Infliximab. Diabetes Care 2019;42:e153–e154
B. Trinh, M.Y. Donath, and H. Laubli

e12 Comment on Jakubowicz et al. Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial. Diabetes Care 2019;42:2171–2180
I.E. Saraiva

e13 Response to Comment on Jakubowicz et al. Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial. Diabetes Care 2019;42:2171–2180
O. Froy